Macroview Investment Management’s Biogen BIIB Stock Holding History

Macroview Investment Management’s Portfolio BIIB Stock Details BIIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-50	Closed	-$13K	–	466
2022 Q3	$13K	Buy	+50	New	+$10.6K	0.02%	137
2019 Q4	–	Sell	-18	Closed	-$4K	–	302
2019 Q3	$4K	Buy	18 +1	+6%	+$233	0.01%	176
2019 Q2	$4K	Buy	+17	New	+$3.92K	0.01%	177
2018 Q4	–	Sell	-12	Closed	-$4K	–	331
2018 Q3	$4K	Buy	+12	New	+$4.13K	0.01%	164
2015 Q1	–	Sell	-2	Closed	-$1K	–	145
2014 Q4	$1K	Hold	2	–	–	﹤0.01%	150
2014 Q3	$1K	Buy	+2	New	+$659	﹤0.01%	159
2014 Q2	–	Sell	-13	Closed	-$4K	–	193
2014 Q1	$4K	Buy	+13	New	+$4.13K	0.01%	167

Other funds holding BIIB

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Macroview Investment Management's BIIB Position: Q4 2022 in Review

Macroview Investment Management sold out of Biogen (BIIB) in Q4 2022, closing a stake of 50 shares — an estimated $13K sold.

Macroview Investment Management first reported a position in BIIB in Q1 2014 and held it in 7 quarters. The position peaked at $13K in Q3 2022. 1,031 funds tracked by Wall St. Rank hold BIIB as of Q4 2022.

Macroview Investment Management reported no remaining Biogen position as of Q4 2022 after selling out during the quarter.
Macroview Investment Management sold 50 Biogen shares in Q4 2022, an estimated $13K.
Macroview Investment Management first reported a position in Biogen in Q1 2014 and held it in 7 quarters.
Macroview Investment Management's Biogen position peaked at $13K in Q3 2022.
1,031 funds tracked by Wall St. Rank held Biogen as of Q4 2022.

Based on Macroview Investment Management's 13F filing for Q4 2022, filed 11 Jan 2023.